Results for
""Nelfinavir""[mesh_terms]

Atazanavir demonstrates antiviral efficacy and a favorable lipid profile at 48 weeks.

The Journal of the Association of Nurses in AIDS Care : JANAC 2002;13(2):86-7

Prediction of Binding Pose and Affinity of Nelfinavir, a SARS-CoV-2 Main Protease Repositioned Drug, by Combining Docking, Molecular Dynamics, and Fragment Molecular Orbital Calculations.

Shigenori Tanaka, Yusuke Kawashima, Kaori Fukuzawa, Yuji Mochizuki, Teruki Honma, Yuma Handa, Koji Okuwaki, Ryo Hatada, Yuto Komeiji, Takayuki Furuishi, Etsuo Yonemochi

The journal of physical chemistry. B 2024;128(10):2249-2265

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.

P H Hsyu, M D Schultz-Smith, J H Lillibridge, R H Lewis, B M Kerr

Antimicrobial agents and chemotherapy 2002;45(12):3445-50

A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Richard E Kast, John A Boockvar, Ansgar Brüning, Francesco Cappello, Wen-Wei Chang, Boris Cvek, Q Ping Dou, Alfonso Duenas-Gonzalez, Thomas Efferth, Daniele Focosi, Seyed H Ghaffari, Georg Karpel-Massler, Kirsi Ketola, Alireza Khoshnevisan, Daniel Keizman, Nicolas Magné, Christine Marosi, Kerrie McDonald, Miguel Muñoz, Nathan Sassoon, Mohammad H Pourgholami, Iacopo Sardi, Avishay Sella, Kalkunte S Srivenugopal, Marco Tuccori, Weiguang Wang, Christian R Wirtz, Marc-Eric Halatsch

Oncotarget 2013;4(4):502-30

Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.

C S Vasavi, Ramasamy Tamizhselvi, Punnagai Munusami

Journal of molecular graphics & modelling 2018;75():390-402

Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.

P O Markgren, M T Lindgren, K Gertow, R Karlsson, M Hämäläinen, U H Danielson

Analytical biochemistry 2001;291(2):207-18

Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.

Muki S Shey, Eugene J Kongnyuy, Samuel M Alobwede, Charles Shey Wiysonge

The Cochrane database of systematic reviews 2013;2013(3):CD005481

A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.

Muki Shey, Eugene J Kongnyuy, Judith Shang, Charles Shey Wiysonge

The Cochrane database of systematic reviews 2009

The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.

Nancy L Sheehan, Rolf P G van Heeswijk, Brian C Foster, Humayoun Akhtar, Neera Singhal, Isabelle Seguin, Lina DelBalso, Marc Bourbeau, Bobby M Chauhan, Mohammed-Rachid Boulassel, David M Burger, Richard G Lalonde, Donald William Cameron

Molecules (Basel, Switzerland) 2012;17(1):688-702

The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.

U S Justesen, I M Hansen, A B Andersen, N A Klitgaard, F T Black, J Gerstoft, L R Mathiesen, C Pedersen

HIV medicine 2006;6(5):334-40

A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.

Cesar Fisac, Nuria Virgili, Elena Ferrer, Maria J Barbera, Emilio Fumero, Concepcio Vilarasau, Daniel Podzamczer

The Journal of clinical endocrinology and metabolism 2003;88(11):5186-92

Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.

Robin Wood, Praphan Phanuphak, Pedro Cahn, Vadim Pokrovskiy, Willy Rozenbaum, Giuseppe Pantaleo, Michael Sension, Robert Murphy, Marco Mancini, Thomas Kelleher, Michael Giordano

Journal of acquired immune deficiency syndromes (1999) 2005;36(2):684-92

Systems Pharmacology Identifies an Arterial Wall Regulatory Gene Network Mediating Coronary Artery Disease Side Effects of Antiretroviral Therapy.

Itziar Frades, Ben Readhead, Letizia Amadori, Simon Koplev, Husain A Talukdar, Heidi M Crane, Paul K Crane, Jason C Kovacic, Joel T Dudley, Chiara Giannarelli, Johan L M Björkegren, Inga Peter

Circulation. Genomic and precision medicine 2020;12(6):e002390

HIV protease as a target for retrovirus vector-mediated gene therapy.

S Todd, C Anderson, D J Jolly, C S Craik

Biochimica et biophysica acta 2000;1477(1-2):168-88

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

Ian Sanne, Peter Piliero, Kathleen Squires, Alexandra Thiry, Steven Schnittman

Journal of acquired immune deficiency syndromes (1999) 2003;32(1):18-29